<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238588</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002213</org_study_id>
    <nct_id>NCT01238588</nct_id>
  </id_info>
  <brief_title>The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan</brief_title>
  <official_title>The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will
      be associated with less inflammation including less atherosclerotic plaque inflammation
      (inflammation of the vessel walls).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study stopped due to lack of funding.
  </why_stopped>
  <start_date type="Actual">June 10, 2011</start_date>
  <completion_date type="Actual">April 8, 2016</completion_date>
  <primary_completion_date type="Actual">April 8, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET): FDG-PET/CT Dual Scan Score</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in High Sensitivity C-Reactive Protein (Hs-CRP) Level</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Interleukin-6 (IL-6) Level</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin Levels</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoiesis Stimulating Agent (ESA) Dose Requirement</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cardiovascular Events</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis Access Stenosis/Thrombosis</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dialysis</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Atherosclerosis</condition>
  <condition>Inflammation</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Sevelamer Carbonate (Renvela)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate (Renvela)</intervention_name>
    <description>Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
    <arm_group_label>Sevelamer Carbonate (Renvela)</arm_group_label>
    <other_name>Sevelamer carbonate</other_name>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed consent form;

          -  Male or Female, 50 years or older;

          -  Diagnosed with end stage renal disease (ESRD), on maintenance hemodialysis for at
             least three (3) months;

          -  On calcium-based phosphate binders;

          -  Subject must be able to understand and provide informed consent;

          -  No known contraindications to therapy with sevelamer carbonate.

        Exclusion Criteria:

          -  Any patient with a medical condition or taking any medications that would be
             contraindicated with the use of sevelamer carbonate, such as history of bowel
             obstruction;

          -  History of severe allergic reactions to the study medication;

          -  History of active infection (other than a simple respiratory tract infection) or acute
             gouty attack within 2 weeks prior to enrollment;

          -  Known serological positivity for Human Immunodeficiency Virus (HIV), Hepatitis B
             surface Antigen (HBsAg), or Hepatitis C Virus Antibody (HCV Ab) except dose with
             normal liver function tests (AST, ALT, Bilirubin, and Alkaline Phophatase) and no
             history of cirrhosis;

          -  Elevation of liver function tests at time of entry (Aspartate Aminotransferase (AST)
             and/or Alanine Aminotransferase (ALT) &gt; 2 times the upper limit of normal);

          -  History of drug, alcohol, or chemical abuse within 6 months prior to enrollment;

          -  History of malignancy except those adequately treated, has completed treatment and
             clinically in remission for more than 6 month; adequately treated in-situ cervical
             carcinoma, or adequately treated basal or squamous cell carcinoma of the skin;

          -  History of an inflammatory disease such as systemic lupus erythematosus (SLE),
             rheumatoid arthritis or ulcerative colitis except those in remission for more than 6
             months;

          -  Patients currently on sevelamer carbonate or sevelamer chloride or history of taking
             them for more than a week in the past three months;

          -  Patients receiving chronic anti-inflammatory therapy;

          -  Patients in whom FDG-PET/CT dual scans are contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kambiz Zandi-Nejad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Boston-TKC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BWH/FH/DCI Outpatient Dialysis Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Framingham (#1109)</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Marlborough (#3448)</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medford Dialysis (#1246)</name>
      <address>
        <city>Medford</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Quincy (#1610)</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Roxbury (#1630)</name>
      <address>
        <city>Roxbury</city>
        <state>Massachusetts</state>
        <zip>02119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCI Dialysis Unit-Somerville</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius QCDC-Weymouth (#9144)</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <results_first_submitted>May 26, 2017</results_first_submitted>
  <results_first_submitted_qc>May 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2017</results_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Kambiz Zandi-Nejad, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>24 patients enrolled in the study by signing the consent form of which 12 started the study. The other 12 never started the study due to various reasons (eg voluntary withdrawal, termination due to infection, transplant).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sevelamer Carbonate (Renvela)</title>
          <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sevelamer Carbonate (Renvela)</title>
          <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET): FDG-PET/CT Dual Scan Score</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Scans were done but not analyzed due to early study termination (per funding source).</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET): FDG-PET/CT Dual Scan Score</title>
          <population>Scans were done but not analyzed due to early study termination (per funding source).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in High Sensitivity C-Reactive Protein (Hs-CRP) Level</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Blood samples were collected but the measurements were not done due to early study termination (per funding source).</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in High Sensitivity C-Reactive Protein (Hs-CRP) Level</title>
          <population>Blood samples were collected but the measurements were not done due to early study termination (per funding source).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Interleukin-6 (IL-6) Level</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Blood samples were collected but the measurements were not done due to early study termination (per funding source).</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Interleukin-6 (IL-6) Level</title>
          <population>Blood samples were collected but the measurements were not done due to early study termination (per funding source).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin Levels</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Clinical lab data for this outcome measure was not collected from the medical record (for research purpose) due to early termination of the study (per funding source)</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin Levels</title>
          <population>Clinical lab data for this outcome measure was not collected from the medical record (for research purpose) due to early termination of the study (per funding source)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythropoiesis Stimulating Agent (ESA) Dose Requirement</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Data for this outcome measure was not collected from the medical record due to early termination of the study (per funding source).</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythropoiesis Stimulating Agent (ESA) Dose Requirement</title>
          <population>Data for this outcome measure was not collected from the medical record due to early termination of the study (per funding source).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Level</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Clinical lab data for this outcome measure was not collected from the medical record (for research purpose) due to early termination of the study (per funding source)</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Level</title>
          <population>Clinical lab data for this outcome measure was not collected from the medical record (for research purpose) due to early termination of the study (per funding source)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Cardiovascular Events</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Data for this outcome measure was not collected from the medical record due to early termination of the study (per funding source).</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Cardiovascular Events</title>
          <population>Data for this outcome measure was not collected from the medical record due to early termination of the study (per funding source).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodialysis Access Stenosis/Thrombosis</title>
        <time_frame>Baseline and 6 months</time_frame>
        <population>Data for this outcome measure was not collected from the medical record due to early termination of the study (per funding source).</population>
        <group_list>
          <group group_id="O1">
            <title>Sevelamer Carbonate (Renvela)</title>
            <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Access Stenosis/Thrombosis</title>
          <population>Data for this outcome measure was not collected from the medical record due to early termination of the study (per funding source).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sevelamer Carbonate (Renvela)</title>
          <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
Sevelamer Carbonate (Renvela): Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was much slower than anticipated due to logistical reasons, study at the direction of funding source terminated early and therefore none of the collected samples were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kambiz Zandi-Nejad</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-5500 ext 34769</phone>
      <email>kzandinejad@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

